Evidence map›Paper›PMID 38076851›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Rostislav Skitchenko, Zora Modrusan, Alexander Loboda, Jeffrey B Kopp, Cheryl A Winkler, Alexey Sergushichev, Namrata Gupta, Christine Stevens, Mark J Daly, Andrey Shaw and 1 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

  • Updated by
    2025
5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Rostislav SkitchenkoITMO University, St. Petersburg, Russia.
Zora ModrusanResearch Biology, Genentech Inc., San Francisco, CA, USA.
Alexander LobodaITMO University, St. Petersburg, Russia.
Jeffrey B KoppKidney Disease Section, Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, Maryland, USA.
Cheryl A WinklerMolecular Genetic Epidemiology Studies Section, National Cancer Institute (NCI), Frederick, Maryland, USA.
Alexey SergushichevITMO University, St. Petersburg, Russia.
Namrata GuptaBroad Institute, Cambridge, MA, USA.
Christine StevensBroad Institute, Cambridge, MA, USA.
Mark J DalyBroad Institute, Cambridge, MA, USA.
Andrey ShawResearch Biology, Genentech Inc., San Francisco, CA, USA.
Mykyta ArtomovBroad Institute, Cambridge, MA, USA.
Broad Institute · USITMO University · RUNational Cancer Institute · USNational Institute of Diabetes and Digestive and Kidney Diseases · US

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
NCI NIH HHS 75N91019D00024
6 · The paper itself

Abstract

Focal segmental glomerulosclerosis (FSGS) is a common cause of nephrotic syndrome with an annual incidence in the United States in African-Americans compared to European-Americans of 24 cases and 5 cases per million, respectively. Among glomerular diseases in Europe and Latin-America, FSGS was the second most frequent diagnosis, and in Asia the fifth. We expand previous efforts in understanding genetics of FSGS by performing a case-control study involving ethnically-diverse groups FSGS cases (726) and a pool of controls (13,994), using panel sequencing of approximately 2,500 podocyte-expressed genes. Through rare variant association tests, we replicated known risk genes -

Identifiers

PMID38076851
PMCPMC10705641
OpenAlexW4388849325

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.